Raw lab data of Fecal Calprotectin, Serum Ferritin and C-Reactive Protein in Individuals Suffering from Inflammatory Bowel Disease with coexistent Type 2 Diabetes Mellitus in Latvia
Description
This is the data set for publication of: "Elevated Fecal Calprotectin, Serum Ferritin and C-Reactive Protein in Individuals Suffering from Inflammatory Bowel Disease with coexistent Type 2 Diabetes Mellitus", Sargautiene et al. This retrospective database study compares laboratory data from patients with IBD who have T2DM (IBD with T2DM) with patients who have IBD but do not have T2DM. The studied dataset, comprising laboratory tests and disease records, comes from Latvia's clinical laboratory, "E. Gulbis Laboratory" (EGL), situated in Riga, Latvia. Data generation relied on the EGL database, which documents and stores clinical data obtained during patient laboratory visits. All patient data used in this study were subjected to deidentified measures to protect privacy. All patient data used in this study was anonymized before its use. To ensure the distinctiveness of each patient, a unique identification number was assigned to them during their initial visit to the EGL laboratory. This identifier remained unchanged for all subsequent analyses, facilitating the accurate tracking and differentiation of individual patients within the study. Unique number was additionally depersonalised in current data set by assigning unique number coded as "PATNR".
Files
Steps to reproduce
Laboratory data was extracted from databases using specific criteria and filters. Initially, individuals aged 18 and above with IBD were identified within a 5-year timeframe, based on their registration and completion of laboratory blood tests. Each patient in the database was assigned a unique identifier during their initial visit, ensuring anonymity while enabling continuous tracking across subsequent visits. The investigation focused on analyzing patient demographics (age, gender) and laboratory parameters (serum C-reactive protein (CRP), ferritin (SF), calprotectin (CALP)). All specified laboratory tests conducted on these subgroups during the specified period were considered.